BioCentury
ARTICLE | Company News

Spectrum Pharmaceuticals cancer news

October 15, 2012 7:00 AM UTC

Spectrum said that the U.S. Patent and Trademark Office (PTO) extended by five years U.S. Patent No. 6,028,071 covering cancer drug Folotyn pralatrexate. The extension postpones the original July 16...